Results Set a High Standard in Sustained Long Term Clinical Outcomes SUNNYVALE, Calif.--(Healthcare Sales & Marketing Network)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceutica...
Devices, Interventional Cardiology
Elixir Medical, DESyne BD, Novolimus, drug eluting stent

DUBLIN--(Healthcare Sales & Marketing Network)--Covidien plc (COV), a leading global provider of healthcare products, today announced that its board of directors has approved the separation of the Pharmaceuticals business from the rest of Covidien. The sep...
Biopharmaceuticals
Covidien, Mallinckrodt

LONDON, May 24, 2013 -- (Healthcare Sales & Marketing Network) --Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrenc...
Biopharmaceuticals, Regulatory
Norgine, Alfa Wassermann, XIFAXAN, TARGAXAN, hepatic encephalopathy

TOKYO & SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Astellas Pharma Inc. (TOKYO:4503) and Medivation, Inc. (MDVN) today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of...
Biopharmaceuticals, Oncology, Regulatory
Astellas Pharma, Medivation, enzalutamide, XTANDI , prostate cancer

WARSAW, Ind.--(Healthcare Sales & Marketing Network)--Biomet, Inc., a global leader in the manufacture of orthopaedic and biotechnology products, announces the presentation of research that included an evaluation of patient satisfaction with its Oxford Par...
Devices, Orthopaedic
Biomet , Oxford Partial Knee, Partial Knee, total knee

Kona Surround Sound® Technology Utilizes Externally-Delivered Ultrasound to Treat Drug-Resistant Hypertension BELLEVUE, Wash. & MENLO PARK, Calif.--(Healthcare Sales & Marketing Network)--Kona Medical announced that three and six month results from...
Devices, Cardiology
Kona Medical, Surround Sound, Renal Denervation, hypertension

Fewer Pressure Ulcers and Better Use of Nursing Time Also Cited SKILLMAN, N.J., May 23, 2013 -- (Healthcare Sales & Marketing Network) -- A new study of the costs of managing fecal incontinence in intensive care units (ICUs) at two Canadian hospitals h...
Devices, Wound Care
ConvaTec, fecal incontinence, Flexi-Seal, pressure ulcer

Addition of Renowned Scientist Underscores Commitment to Vibrant and Innovative Scientific Research WESTON, Mass.--(Healthcare Sales & Marketing Network)--Biogen Idec (BIIB) today announced that Spyros Artavanis-Tsakonas, Ph.D., has been named the compa...
Biopharmaceuticals, Personnel
Biogen Idec

NEW PROVIDENCE, N.J.--(Healthcare Sales & Marketing Network)--Final 6 and 12-month results of the DIRECT first-in-man clinical study were presented by study principal investigator Dr. Mark Webster at the late-breaking clinical trials session of the EuroPCR...
Devices, Interventional Cardiology
Svelte Medical Systems, sirolimus, drug eluting stent

Company to Host Conference Call Today at 8:00am ET, 2:00pm CET PARIS, May 23, 2013 -- (Healthcare Sales & Marketing Network) --InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents,...
Devices, Interventional Cardiology
InspireMD, embolic protection, MGuard , Embolic Protection Stent

ST. PAUL, Minn. & PARIS--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (STJ), a global medical device company, today announced that the company’s EnligHTN™ Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduc...
Devices, Cardiology
St. Jude Medical, EnligHTN, Renal Denervation, drug-resistant hypertension

Netherlands first to approve new fixed-dose combination treatment for men with lower urinary tract symptoms associated with BPH CHERTSEY, England, May 23, 2013 -- (Healthcare Sales & Marketing Network) --ASTELLAS PHARMA EUROPE B.V., the European subsid...
Biopharmaceuticals, Urology, Regulatory
Astellas Pharma Europe, VESOMNI, benign prostatic hyperplasia

PARIS, May 22, 2013 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for corona...
Devices, Interventional Cardiology
Boston Scientific, Promus PREMIER, Drug Eluting Stent

Benefits of surgical incision management now available to more patients SAN ANTONIO--(Healthcare Sales & Marketing Network)--Kinetic Concepts, Inc. today launched a Prevena™ Peel & Place™ Dressing with a V.A.C.® Connector, which expands the availabi...
Devices, Surgery, Wound Care, Product Launch
Kinetic Concepts, Prevena, Peel & Place, negative pressure wound therapy

WOODCLIFF LAKE, N.J., May 22, 2013 -- (Healthcare Sales & Marketing Network) -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca to distribute the authorized g...
Biopharmaceuticals, Cardiology, Generics, Distribution
Par Pharmaceutical, Atacand, candesartan cilexetil, AstraZeneca

Dr. Olson’s Extensive Experience in Personalized Medicine Will Support Syros’ Mission to Lead in Gene Control WATERTOWN, Mass.--(Healthcare Sales & Marketing Network)--Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene cont...
Biopharmaceuticals, Personalized Medicine, Personnel
Syros Pharmaceuticals

NEW YORK, May 22, 2013 -- (Healthcare Sales & Marketing Network) -- Ohr Pharmaceutical Inc. (OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of June S. Almenoff, M.D...
Biopharmaceuticals, Personnel
Ohr Pharmaceutical, macular degeneration, cancer cachexia

CAMBRIDGE, Mass., May 22, 2013 -- (Healthcare Sales & Marketing Network) -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic protein...
Biopharmaceuticals, Personnel
Moderna Therapeutics, RNA therapeutics, John Reynders

Endoscopic ablation in patients with Barrett’s esophagus containing confirmed low-grade dysplasia reduces the relative risk for disease progression by 94% as compared to controls ORLANDO, Fla.--(Healthcare Sales & Marketing Network)--Covidien (COV), a l...
Devices, Gastroenterology
Covidien, endoscopic ablation, Barrett’s esophagus, Barrx, SURF Trial

Results of Randomized JACK-EPC Trial Published in Minerva Cardioangiologica HONG KONG, May 22, 2013 -- (Healthcare Sales & Marketing Network) -- OrbusNeich( http://www.orbusneich.com ) today announced that the company's Genous Stent is associated with ...
Devices, Interventional Cardiology
OrbusNeich, Genous Stent, restenosis, JACK-EPC